NT-proBNP changes may refine CVD risk in older adults

What happened

A study published Aug. 18, 2026, in the Annals of Internal Medicine reports that changes in NT-proBNP over three years may help stratify cardiovascular disease (CVD) and mortality risk in community-dwelling older adults.

The researchers grouped people by “heart stress” status using serial NT-proBNP measurements taken at trial enrollment and again at year 3, then followed participants for CVD events and deaths.

• Population: 8,454 community-dwelling older adults without prior CVD
• Exposure: three-year change in NT-proBNP (“heart stress” status)
• Outcomes: total CVD events and all-cause mortality
• Follow-up: median 8.0 years

What the evidence actually shows about NT-proBNP and cardiovascular risk

This was an observational analysis examining the association between categories of NT-proBNP change and later outcomes in older adults free of prior CVD at baseline.

During follow-up, the researchers identified 818 CVD events and 1,584 deaths, and they reported higher adjusted absolute risks at year 8 for some “heart stress” categories compared with people who stayed “heart stress–free.”

• Heart stress categories: persistently HS-free, HS remission, incident HS, sustained HS
• Adjusted absolute risk increase for total CVD at year 8: +7.4% (incident HS) and +6.7% (sustained HS) vs persistently HS-free
• Adjusted absolute risk increase for all-cause mortality at year 8: +6.1% (incident HS) and +7.5% (sustained HS) vs persistently HS-free
• HS remission showed similar adjusted absolute risks to persistently HS-free

Why serial NT-proBNP could matter for risk stratification

These results suggest that looking at NT-proBNP patterns over time—rather than relying on a single value—may add information for CVD and mortality risk stratification in older adults.

The authors note that future studies should test whether using “heart stress” status from serial NT-proBNP values can inform care in ways that reduce CVD and mortality risk in an older adult population.

• A single NT-proBNP measurement may miss whether risk is rising or improving
• “Incident” and “sustained” heart stress patterns were associated with higher absolute risks in this analysis
• “Remission” (improvement) tracked closer to persistently low heart stress in adjusted absolute risk estimates

Practical context for metabolic-health readers

If you and your clinician already use lab testing as part of long-term cardiometabolic risk review, this study highlights a specific idea to discuss: whether repeating NT-proBNP over time could refine how risk is categorized in older adults without known CVD.

Because the study focuses on community-dwelling older adults and relates NT-proBNP change to later CVD and mortality outcomes, its main practical value is as a risk-assessment signal to bring into clinician-led decision-making, not as a standalone answer.

• Bring the study’s framing to visits: “serial NT-proBNP” and “three-year change” rather than a one-time number
• Ask how any biomarker trend would be interpreted alongside traditional risk factors and symptoms
• Use results as context for questions about monitoring plans, not as a diagnosis or a treatment plan

Limitations and caveats to keep in mind

This study reports associations between NT-proBNP change categories and later CVD events and all-cause mortality; it does not establish that changing NT-proBNP causes the outcomes or that acting on these categories will prevent them.

The findings apply to community-dwelling older adults without prior CVD who had NT-proBNP measured at enrollment and at year 3, so it is not clear from this report how well the same approach works in other age groups or in people with established CVD.

• Association, not proof of benefit from an intervention
• Two measurement time points (enrollment and year 3) define the change categories
• The study calls for future research on whether this approach can inform care to reduce risk